A new research paper was published in Oncotarget’s Volume 15 on May 16, 2024, entitled, “The anticancer potential of the CLK kinases inhibitors 1C8 and GPS167 revealed by their impact on the epithelial-mesenchymal transition and the antiviral immune response.”
Apellis Pharmaceuticals Inc Patent: Treatment of Complement-Mediated Eye Disorder
Share this article According to GlobalData’s company profile on Apellis Pharmaceuticals, Cyclosporin derivatives was a key innovation area identified from patents. Apellis Pharmaceuticals‘s grant share